NCT02113397View on ClinicalTrials.gov

Evaluation of Inhaled Antibiotics on Bacterial Diversity and Richness in the Cystic Fibrosis Lung

TerminatedOBSERVATIONAL

Enrollment

1

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions

Cystic Fibrosis

Interventions

DRUG

TOBI™ Podhaler™ 112 mg inhaled twice daily

DRUG

Colistimethate 75 mg inhaled two times daily

Trial Locations (1)

03756

Dartmouth-Hitchcock Medical Center, Lebanon

Sponsors

Collaborators (1)

Novartis Pharmaceuticals

All Listed Sponsors

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Dartmouth-Hitchcock Medical Center

OTHER